新型抗IL-4受体α单抗Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展  

Research progress of dupilumab, a novel monoclonal antibody to the α-subunit of interleukin-4 receptor in treatment of persistent moderate-to-severe asthma with elevated eosinophil levels

作　　者：谢林艳[1] 柏芳芳 陈子[1] 周林福[1,2] 

机构地区：[1]南京医科大学第一附属医院呼吸内科,210029 [2]江苏盛泽医院(江苏省人民医院盛泽分院)呼吸内科,苏州215228

出　　处：《中华临床医师杂志（电子版）》2015年第15期88-92,共5页Chinese Journal of Clinicians(Electronic Edition)

基　　金：国家自然科学基金(81370133;81170018);江苏省医学重点人才项目(RC2011066);江苏省333高层次人才培养工程(201115);江苏省高校自然科学研究项目(11KJB320008);江苏省高校优势学科建设工程(JX10231801);江苏省临床医学科技专项(BL2012012);苏州市科技计划项目(SYS201402)

摘　　要：支气管哮喘是一种以Th2优势免疫为特征的气道过敏性疾病,其中嗜酸粒细胞性气道炎症、气道高反应性和气道重塑为哮喘三个主要的临床特征。Dupilumab是抗IL-4受体α亚基(IL-4Rα)的单抗,能抑制IL-4Rα与IL-4和IL-13结合并阻断其介导的下游信号转导,从而抑制哮喘气道炎症、气道高反应性和气道重塑的发生发展。本文将就Dupilumab治疗嗜酸粒细胞增高的中重度持续性哮喘的研究进展作一综述。Bronchial asthma is a Th2 immunity-dominated common airway allergic disease, characterized by eosinophilic airway inflammation, airway hyperresponsiveness and airway remodeling. Dupilumab,a novel monoclonal antibody targeting the α-subunit of IL-4 receptor （IL-4Rα）, is capable of binding with IL-4Rα to block both IL-4 and IL-13-mediated signaling pathways, leading to inhibit the airway inflammation, hyperresponsiveness and remodeling. This paper focused on the progress of Dupilumab in persistent moderate-to-severe asthma with elevated eosinophil levels.

关 键 词：哮喘 白细胞介素4 白细胞介素13 嗜酸粒细胞 

分 类 号：R562.25[医药卫生—呼吸系统]